Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.56 |
| ▸ | HTR1A | P08908 | 1/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.52 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | CMA1 | P23946 | 1/20 | 0.48 |
| ▸ | PDE4A | P27815 | 1/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.47 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | CLPP | Q16740 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14177592 | 0.88 | HTR1A (0.62) | SIGMAR1HTR1ASLC6A4ROCK2KMT2A | |
| SCHEMBL14177630 | 0.85 | ALDH1A1 (0.55) | KMT2AMEN1CMA1 | |
| SCHEMBL6733710 | 0.84 | HSD11B1 (0.57) | ROCK2KMT2AMEN1HDAC1HDAC8 | |
| SCHEMBL14177626 | 0.83 | MAPT (0.51) | SIGMAR1CMA1CLPP | |
| SCHEMBL13717039 | 0.83 | GRM2 (0.49) | SIGMAR1KMT2AMEN1PDE4APDE4B | |
| SCHEMBL7001262 | 0.83 | MEN1 (0.57) | SIGMAR1KMT2AMEN1 | |
| SCHEMBL14177621 | 0.82 | CYP19A1 (0.48) | SIGMAR1 | |
| SCHEMBL8562278 | 0.82 | SIGMAR1 (0.55) | SIGMAR1KMT2ACMA1PKM | |
| SCHEMBL8562273 | 0.82 | SIGMAR1 (0.55) | SIGMAR1KMT2ACMA1PKM | |
| SCHEMBL14177629 | 0.80 | OPRK1 (0.50) | SIGMAR1KMT2AMEN1CMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9776965-B2 | Pyrrolidin-2-one and piperidin-2-one derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2017-10-03 | — | — | US | disclosed |
| US-9776965-B2 | Pyrrolidin-2-one and piperidin-2-one derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2017-10-03 | — | — | US | disclosed |
| US-20160168094-A1 | PYRROLIDIN-2-ONE AND PIPERIDIN-2-ONE DERIVATIVES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-06-16 | — | — | US | disclosed |
| US-20160168094-A1 | PYRROLIDIN-2-ONE AND PIPERIDIN-2-ONE DERIVATIVES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-06-16 | — | — | US | disclosed |
| US-9302987-B2 | Pyrrolidinyl derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2016-04-05 | — | — | US | disclosed |
| US-9302987-B2 | Pyrrolidinyl derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2016-04-05 | — | — | US | disclosed |
| US-20150183735-A1 | PYRROLIDINYL DERIVATIVES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-07-02 | — | — | US | disclosed |
| US-20150183735-A1 | PYRROLIDINYL DERIVATIVES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-07-02 | — | — | US | disclosed |
| US-9012494-B2 | Pyrrolidin-2-one and piperidin-2-one derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2015-04-21 | — | — | US | disclosed |
| US-9012494-B2 | Pyrrolidin-2-one and piperidin-2-one derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2015-04-21 | — | — | US | disclosed |
| US-20080139625-A1 | Metabolic syndrome; compounds are 1,3-substituted-2-oxo-(pyrrolidines or piperidines); 3-[(2,6-Dichlorophenyl)methyl]-1-(1-phenylpropyl)-2-pyrrolidinone for example | INSTITUTE OF ORGANIC CHEMISTRY, BULGARIAN ACADEMY OF SCIENCES (BG) | 2008-06-12 | — | — | US | disclosed |
| US-20080139625-A1 | Metabolic syndrome; compounds are 1,3-substituted-2-oxo-(pyrrolidines or piperidines); 3-[(2,6-Dichlorophenyl)methyl]-1-(1-phenylpropyl)-2-pyrrolidinone for example | INSTITUTE OF ORGANIC CHEMISTRY, BULGARIAN ACADEMY OF SCIENCES (BG) | 2008-06-12 | — | — | US | disclosed |
| WO-2004075847-A2 | METHODS AND COMPOUNDS FOR THE TREATMENT OF Aß ASSOCIATED DISEASES, DISORDERS, AND CONDITIONS | MESSAGE PHARMACEUTICALS, INC. (US) | 2004-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150183735-A1 | PYRROLIDINYL DERIVATIVES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS | HSD11B1, HSD3B1, HSD11B2 | SIGMAR1 477/4885HTR1A 632/4885SLC6A4 1213/4885 |
| US-20160168094-A1 | PYRROLIDIN-2-ONE AND PIPERIDIN-2-ONE DERIVATIVES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS | HSD3B1, HSDL2, HSD11B1 | SIGMAR1 692/4885HTR1A 666/4885SLC6A4 1888/4885 |
| US-20080139625-A1 | Metabolic syndrome; compounds are 1,3-substituted-2-oxo-(pyrrolidines or piperidines); 3-[(2,6-Dichlorophenyl)methyl]-1-(1-phenylpropyl)-2-pyrrolidinone for example | NAT1, CBR1, PC | SIGMAR1 532/4885HTR1A 471/4885SLC6A4 1408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.